BiologicsMD Uses Unique Fusion Proteins To Treat Alopecia Safely
Emerging Company Profile: The US biotech is developing a series of recombinant fusion proteins to tackle alopecia and other diseases without supressing the immune system.
You may also be interested in...
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.
The US firm released promising interim data from a mid-stage Becker muscular dystrophy trial, claiming success here could translate to Duchenne as it unveiled plans for more studies across similar conditions.
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.